(171010) – Predicted skin uptake potential for a number of cosmetic ingredients (to demonstrate that our in-silico tools could replace animal experiments).
(160907) New customer + first prospective validation of customer substance in clinical trials (1.2-fold average prediction error)
(160824) Signed significant long-term deal with major international pharma company – Prosilico to deliver 20000+ key human ADME/PK-estimates
(160809) New customer
(160608) Speaker at BIO Hanse meeting in Stockholm
(160520) Delivered 800 parameter estimates to customer
(160503) Signed an international subscription contract
(160404-6) Attended BIO-Europe in Stockholm.
(160330) Speaker at New Updates in Drug Formulations and Bioavailability March 30 in Copenhagen.
(160212) Clearly ourperformed two big pharma companies predicting PK of 8 metabolically stable compounds.
(160211) Delivered ocular permeability results to customer
(160127) Developed and validated a reliable (Q^2=0.8) method for prediction of eye/ocular permeability
(160122) Correct prediction of the PK in mice for a customer.
(160122) Attended the 2nd BBB-symposium in Uppsala, Sweden.
(160119) Invited speaker at the “New Updates in Drug Formulations and Bioavailability”-meeting March 30 in Copenhagen (http://formulationsbioavailability.com/?utm_campaign=cmp_507231&utm_medium=email&utm_source=getanewsletter).
(151216) Summary of external validations of predictions of t½ and CL/F (n=22) – 1.3-fold median error and 86 % <3-fold error for t½; 2.2-fold median error and 76 % <3-fold error for CL/F.
(151123-25) Trip to Gothenburg. Gave 3 seminars/company presentations for 8 companies. Initiated a collaboration with Gothenburg University
(151122) Developed a new model for prediction of inhibition and saturation of gut-wall metabolism and efflux
(151119) Predicted 1300+ parameter estimates for customers this week
(151117) Visit to Finland
(151116) Succeeded in predicting the PK and exposure profiles of a drug and its 5 main metabolites
(151110) Working on 4 customer orders this week (in total 50+ compounds)
(151109) Correct prediction of iv + po rat PK of a compound with moderate permeability and excretion for a customer
(151104) Correct prediction of CNS-dispositon potential of a customer’s substance
(151102) New international customer
(151029) New customer!
(150929) Attending and presenting at “Trends in organic chemistry – How are drugs born?” in Stockholm
(150902) Reduced the prediction error for a drug with complex characteristics by 30-fold vs allometry (state-of-the-art lab method recommended by authorities).
(150827) Developed a prediction model for buccal uptake.
(150822) Milestone reached – Results delivered to our 1st big pharma customer and a 2nd is currently exploring entering a business relationship with us!
(150817) We gave a lecture about our absorption prediction platform and at the Bioavailability/Bioequivalence meeting in Chicago (BABE-2015).
(150814) Finalized a lung uptake model with good prospective predictive performance.
(150813) Used 72 prodrug/drug-pairs to validate our prodrug uptake prediction model (good results).
(150811) Finalized a skin permeability model with good prospective predictive performance.
(150730) A new order from a big pharma company.
(150710) Customer #18
(150707) New customer (#17), a big pharma company.
(150629) Two new customer orders.
(150626) We will attend Nordic Life Science Days in Stockholm Sept 9-10 and Pain Symposium in Aberdeen Sept 28-30 assisting/representing Pharmnovo (http://pharmnovo.com/).
(150625) Read about our collaborati0on with Chemnotia (http://blog.chemnotia.com/).
Virtual design of drug and drug candidate analogues with superior properties.
(150623) Read about us in UIC annual review (uic.se/content/uploads/2014/04/UIC_Annual_review_2014.pdf) – pages 36-37 (in swedish)
(150619) Successful prediction of iv and po PK of two customer compounds in mice and rats (external validation).
(150619) Customer #16 and a new order.
(150617) One new customer order.
(150616) Customer review – “Well predicted! Impressive! Congratulations!”
(150609) New customer (#15).
(150605) New customer (#14).
(150528) New customer Redoxis (www.redoxis.se) (#13 since August 2014).
(150523) Successful prediction of iv and po PK of a customer compound in rats.
(150508) A new customer – Quretech Bio (http://quretech.com/).
(150508) We will visit Boston in August (20th-21st) and meet pharmaceutical companies.
(150502) Urban will attend the BABE-2015 congress in Chicago, August 17-19, and give a speech with the title “Prediction of in-vivo permeability, solubility, BCS-classing, food interactions, fraction absorbed and oral bioavailability using new in-silico methods and algorithms”
(150501) Refined our prediction models for oral bioavailability, hepatic and renal clearance, fraction unbound and t½.
(150423) Finalized our BCRP+MDR1-subtrate prediction models. Results similar to those obtained with in-vitro methods.
(150410) MISTRA-application submitted.
(150326) Delivered results to our 12th customer.
(150320) Successful external validations of clinical ADME/PK of two compounds (a prodrug with complex ADME/PK and a renally excreted compound).
(150319) Urban gave a speech at the BioTech Hanse meeting in Stockholm.
(150309-11) Urban attended the BioEurope-2015 conference in Paris.
(150301) Succeeded with predictions of 2 substances that a customer failed to predict despite 5 years effort and lab resources.
(150212) Successful external validation of clinical ADME/PK for a metabolically stable and excreted compound by customer.
(150211) New prediction models for ID of CYP2C9, CYP2D6 & CYP3A4 – 86 % correct classifications (the consistency between in-vitro labs has been estimated to 94%; 88 % for CYP3A4-substrates).
(150203) Two new customers and 4 new orders.
(150119) Prediction model summary 2014 – 3580 predictions. 1524 excellent (<1.3-fold error) and 2446 highly successful (<2-fold error) predictions of human PK-parameters. 1-5-fold median error 1.5-fold.
Take into consideration that each corresponding prediction at labs cost ca 1000-100000 SEK each and fails to predict in more than 80 % of cases.
(150115) Winner of Nordea’s (via Uppsala Innovation Centre) travel grant for companies with great international potential (25000 SEK)
(150106) Customer reviews – “Your efforts get top grades“, “Sovereign“
(141231) 55 (104) and 144 (101) successful (highly successful) predictions of half-life and bioavailability, respectively, during 2014.
(141217) We welcome new customer Umecrine Cognition (http://www.umecrine.se/cognition/)
(141217) We welcome new customer Anamar (http://anamar.com/)
(141216) PROSILICO recently finalized and validated a prediction method for environmental excretion of drugs (Q^2=0.80; 1.4-fold median error; 44 % < 2-fold error).
(141216) Preliminary results for prediction of the absolute and relative kinetics and exposures of drug metabolites are promising.